JP2016518328A5 - - Google Patents

Download PDF

Info

Publication number
JP2016518328A5
JP2016518328A5 JP2016501667A JP2016501667A JP2016518328A5 JP 2016518328 A5 JP2016518328 A5 JP 2016518328A5 JP 2016501667 A JP2016501667 A JP 2016501667A JP 2016501667 A JP2016501667 A JP 2016501667A JP 2016518328 A5 JP2016518328 A5 JP 2016518328A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
alkoxy
alkyl
gene
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016501667A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016518328A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/024885 external-priority patent/WO2014165232A1/en
Publication of JP2016518328A publication Critical patent/JP2016518328A/ja
Publication of JP2016518328A5 publication Critical patent/JP2016518328A5/ja
Pending legal-status Critical Current

Links

JP2016501667A 2013-03-12 2014-03-12 癌治療のための化合物 Pending JP2016518328A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361777427P 2013-03-12 2013-03-12
US61/777,427 2013-03-12
PCT/US2014/024885 WO2014165232A1 (en) 2013-03-12 2014-03-12 Compounds for treatment of cancer

Publications (2)

Publication Number Publication Date
JP2016518328A JP2016518328A (ja) 2016-06-23
JP2016518328A5 true JP2016518328A5 (https=) 2017-04-13

Family

ID=51659101

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016501667A Pending JP2016518328A (ja) 2013-03-12 2014-03-12 癌治療のための化合物

Country Status (8)

Country Link
US (3) US9713612B2 (https=)
EP (1) EP2968348A4 (https=)
JP (1) JP2016518328A (https=)
KR (1) KR20150125665A (https=)
CN (1) CN105142641A (https=)
AU (1) AU2014248568B2 (https=)
CA (1) CA2905830C (https=)
WO (1) WO2014165232A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2173379B2 (en) 2007-07-02 2023-07-05 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
JP6185463B2 (ja) 2011-07-15 2017-08-23 オンコメッド ファーマシューティカルズ インコーポレイテッド Rspo結合剤およびその使用法
EP2861590B1 (en) * 2012-06-15 2017-10-25 Curegenix Inc. Compound as wnt signaling inhibitor, composition, and use thereof
US9181333B2 (en) 2012-07-13 2015-11-10 Oncomed Pharmaceuticals, Inc. RSPO3 binding agents and uses thereof
CN105142641A (zh) 2013-03-12 2015-12-09 广州源生医药科技有限公司 用于治疗癌症的化合物
CN105348298B (zh) * 2014-07-04 2019-03-19 沈阳中化农药化工研发有限公司 取代芳基吡啶类化合物及其用途
CA2961374A1 (en) 2014-09-16 2016-03-24 Oncomed Pharmaceuticals, Inc. Treatment of fibrotic diseases
MA41123A (fr) * 2014-12-02 2017-10-10 Oncomed Pharm Inc Polythérapie pour le traitement du cancer
AU2016267142B2 (en) * 2015-05-26 2020-12-24 Curegenix Corporation Tumor biomarkers and use thereof
US20180153884A1 (en) 2015-05-31 2018-06-07 Curegenix Corporation Combination compositions for immunotherapy
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
CN105254613A (zh) * 2015-10-08 2016-01-20 苏州云轩医药科技有限公司 具有Wnt信号通路抑制活性的杂环化合物及其应用
WO2017062688A1 (en) * 2015-10-08 2017-04-13 Suzhou Yunxuan Yiyao Keji Youxian Gongsi Wnt signaling pathway inhibitors and therapeutic applications thereof
KR102698411B1 (ko) * 2015-10-08 2024-08-26 쑤저우 운씨엔 이야오 커지 요씨엔 공시 Wnt 신호 전달 경로 억제제 및 이의 치료적 적용
WO2017095918A2 (en) * 2015-12-01 2017-06-08 Oncomed Pharmaceuticals, Inc. Methods for treating cancer using rspo3 antagonists
WO2017162611A1 (en) * 2016-03-21 2017-09-28 Astrazeneca Ab Quinoline-3-carboxamide compounds and their use in treating cancer
WO2017167150A1 (zh) * 2016-03-31 2017-10-05 苏州云轩医药科技有限公司 一种3-氟吡啶杂环化合物及其应用
EP4556575A3 (en) 2016-11-21 2025-10-08 Bruker Spatial Biology, Inc. A method for sequencing nucleic acids
JP7419068B2 (ja) * 2016-12-21 2024-01-22 エージェンシー フォー サイエンス,テクノロジー アンド リサーチ 悪性腫瘍を特定するためのキット及びその使用
AU2018244935A1 (en) * 2017-03-30 2019-08-15 F. Hoffmann-La Roche Ag Naphthyridines as inhibitors of HPK1
CN107441045B (zh) 2017-07-21 2018-10-19 广州源生医药科技有限公司 用于递送Wnt信号通路抑制剂的脂质体制剂及其制备方法
AU2018346597B2 (en) 2017-10-06 2023-07-13 Forma Therapeutics, Inc. Inhibiting Ubiquitin Specific Peptidase 30
EP3794146B1 (en) 2018-05-14 2025-12-10 Bruker Spatial Biology, Inc. Method for identifying a predetermined nucleotide sequence
JP7449242B2 (ja) 2018-05-17 2024-03-13 フォーマ セラピューティクス,インコーポレイテッド ユビキチン特異的ペプチダーゼ30(usp30)阻害剤として有用な縮合二環化合物
CN108685923A (zh) * 2018-06-07 2018-10-23 广州源生医药科技有限公司 Wnt信号通路抑制剂在治疗LGR5阳性癌症中的应用
US10961534B2 (en) 2018-07-13 2021-03-30 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating porphyria
JP7530889B2 (ja) 2018-10-05 2024-08-08 フォーマ セラピューティクス,インコーポレイテッド ユビキチン特異的プロテアーゼ30(usp30)阻害剤として作用する縮合ピロリン
US12365686B2 (en) * 2019-07-08 2025-07-22 Jiangsu Kanion Pharmaceutical Co., Ltd. Compound as porcupine inhibitor and use thereof
CN117088878A (zh) * 2020-10-28 2023-11-21 杭州阿诺生物医药科技有限公司 一种高活性Wnt通路抑制剂化合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011622A1 (en) * 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Amino-substituted compounds, methods, and compositions for inhibiting parp activity
AU2003291403A1 (en) * 2002-11-08 2004-06-03 Neurogen Corporation 3-substituted-6-aryl pyridined as ligands of c5a receptors
PL2157192T3 (pl) 2003-10-10 2014-01-31 Deutsches Krebsforsch Kompozycje do diagnozowania i terapii chorób związanych z nieprawidłową ekspresją futrin (R-spondin)
JP2008501696A (ja) 2004-06-04 2008-01-24 アンフォラ ディスカバリー コーポレーション Atp利用酵素阻害活性を示すキノリンおよびイソキノリン系化合物、ならびにその組成物および使用
EP1838320B1 (en) * 2005-01-07 2014-07-16 Emory University Cxcr4 antagonists for the treatment of medical disorders
WO2008086462A2 (en) 2007-01-11 2008-07-17 Wyeth AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS
US8450344B2 (en) * 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
CA2765053C (en) 2009-06-09 2015-08-18 California Capital Equity, Llc Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling
CN102558173B (zh) 2010-12-31 2015-05-20 广州源生医药科技有限公司 抑制wnt信号传导的化合物、组合物及其应用
ES2797533T3 (es) 2012-02-28 2020-12-02 Novartis Ag Selección de pacientes con cáncer para la administración de inhibidores de la señalización Wnt utilizando el estado mutacional de Rnf43
EP2861590B1 (en) 2012-06-15 2017-10-25 Curegenix Inc. Compound as wnt signaling inhibitor, composition, and use thereof
CN105142641A (zh) 2013-03-12 2015-12-09 广州源生医药科技有限公司 用于治疗癌症的化合物
AU2016267142B2 (en) 2015-05-26 2020-12-24 Curegenix Corporation Tumor biomarkers and use thereof

Similar Documents

Publication Publication Date Title
JP2016518328A5 (https=)
JP2016512547A5 (https=)
JP2016518437A5 (https=)
JP2016040288A5 (https=)
JP2017071634A5 (https=)
JP2016515560A5 (https=)
JP2016501221A5 (https=)
JP2017526674A5 (https=)
JP2015508103A5 (https=)
JP2012092103A5 (https=)
CN105358522A8 (en) Ester derivatives of androgen receptor modulators and methods for their use
JP2018514568A5 (https=)
JP2016526540A5 (https=)
JP2016531126A5 (https=)
JP2012524056A5 (https=)
JP2016515131A5 (https=)
JP2014501766A5 (https=)
JP2017514910A5 (https=)
JP2017524735A5 (https=)
JP2016505614A5 (https=)
JP2016505637A5 (https=)
JP2018527301A5 (ja) アジリジン含有dnaアルキル化剤
JP2015521156A5 (https=)
JP2020502268A5 (https=)
JP2015535257A5 (https=)